Lexaria begins dosing in five-week oral semaglutide study versus Novo’s Wegovy tablets

• Lexaria began dosing on June 14 in a five-week human pilot study of oral DehydraTECH-semaglutide versus Novo Nordisk’s Wegovy tablets.
• Results have not been presented; the readout is expected once the study is completed and reviewed.
• The trial aims to show safety and tolerability consistent with earlier GLP-1 work while delivering overall performance comparable to or better than Wegovy.
• The study tests Lexaria’s first DehydraTECH semaglutide tablet, alongside a capsule version, both formulated with SNAC over multi-week dosing.
• Lexaria positioned the program as a potential catalyst for commercial partnering interest from pharmaceutical companies; the study is funded from existing resources.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606250910ACCESSWRNAPR_____1182053) on June 25, 2026, and is solely responsible for the information contained therein.